The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells

Li, Ding; Yu, Zelei; Wang, Tingting; Li, Yang; Chen, Xianling; Wu, Lixian

doi:10.1016/j.yexcr.2020.111985

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upon its knockdown, the enzymatic action of PARP1 and the proliferation of leukemic cells were drastically limited. Moreover, uc002jit.1-deficient leukemic cells were more susceptible to chemotherapy [152]. Taking into consideration the interdependence between PARP1 and NFκB, it is possible that a combination of PARP and NFκB inhibitors may lead to even higher accumulation of DNA damage in cancer cells and silencing of proinflammatory cascades.…”

Section: Parp Inhibitors In the Direct Treatment Of Hematopoietic Canmentioning

confidence: 99%

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors

Sobczak

Zyma

Robaszkiewicz

2020

Cells

View full text Add to dashboard Cite

Modulation of PARP1 expression, changes in its enzymatic activity, post-translational modifications, and inflammasome-dependent cleavage play an important role in the development of monocytes and numerous subtypes of highly specialized macrophages. Transcription of PARP1 is governed by the proliferation status of cells at each step of their development. Higher abundance of PARP1 in embryonic stem cells and in hematopoietic precursors supports their self-renewal and pluri-/multipotency, whereas a low level of the enzyme in monocytes determines the pattern of surface receptors and signal transducers that are functionally linked to the NFκB pathway. In macrophages, the involvement of PARP1 in regulation of transcription, signaling, inflammasome activity, metabolism, and redox balance supports macrophage polarization towards the pro-inflammatory phenotype (M1), which drives host defense against pathogens. On the other hand, it seems to limit the development of a variety of subsets of anti-inflammatory myeloid effectors (M2), which help to remove tissue debris and achieve healing. PARP inhibitors, which prevent protein ADP-ribosylation, and PARP1‒DNA traps, which capture the enzyme on chromatin, may allow us to modulate immune responses and the development of particular cell types. They can be also effective in the treatment of monocytic leukemia and other cancers by reverting the anti- to the proinflammatory phenotype in tumor-associated macrophages.

show abstract

Section: Parp Inhibitors In the Direct Treatment Of Hematopoietic Canmentioning

confidence: 99%

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors

Sobczak

Zyma

Robaszkiewicz

2020

Cells

View full text Add to dashboard Cite

show abstract

“…Details of the PCR operation was carried out in accordance with previous study (21). Samples of health donor and patients with AML were collected from Henan Cancer Hospital and approved by Medical Ethics Committee of The Affiliated Cancer Hospital of Zhengzhou University (approval no.…”

Section: Quantitative Real-time Pcrmentioning

confidence: 99%

A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia

Li,

Wu,

Cheng

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

BackgroundAs a severe hematological malignancy in adults, acute myeloid leukemia (AML) is characterized by high heterogeneity and complexity. Emerging evidence highlights the importance of the tumor immune microenvironment and lipid metabolism in cancer progression. In this study, we comprehensively evaluated the expression profiles of genes related to lipid metabolism and immune modifications to develop a prognostic risk signature for AML.MethodsFirst, we extracted the mRNA expression profiles of bone marrow samples from an AML cohort from The Cancer Genome Atlas database and employed Cox regression analysis to select prognostic hub genes associated with lipid metabolism and immunity. We then constructed a prognostic signature with hub genes significantly related to survival and validated the stability and robustness of the prognostic signature using three external datasets. Gene Set Enrichment Analysis was implemented to explore the underlying biological pathways related to the risk signature. Finally, the correlation between signature, immunity, and drug sensitivity was explored.ResultsEight genes were identified from the analysis and verified in the clinical samples, including APOBEC3C, MSMO1, ATP13A2, SMPDL3B, PLA2G4A, TNFSF15, IL2RA, and HGF, to develop a risk-scoring model that effectively stratified patients with AML into low- and high-risk groups, demonstrating significant differences in survival time. The risk signature was negatively related to immune cell infiltration. Samples with AML in the low-risk group, as defined by the risk signature, were more likely to be responsive to immunotherapy, whereas those at high risk responded better to specific targeted drugs.ConclusionsThis study reveals the significant role of lipid metabolism- and immune-related genes in prognosis and demonstrated the utility of these signature genes as reliable bioinformatic indicators for predicting survival in patients with AML. The risk-scoring model based on these prognostic signature genes holds promise as a valuable tool for individualized treatment decision-making, providing valuable insights for improving patient prognosis and treatment outcomes in AML.

show abstract

“…As the most common form of acute leukemia in adults, AML remains a devastating disease, with an annual incidence of approximately 16,000 new cases in China and a 5-year overall survival (OS) of only 10% (2). Effective treatment of AML is very challenging (3). For over 4 decades, therapeutic options for AML were limited to highdose cytotoxic chemotherapy, followed by either allogeneic stem cell transplant or consolidation chemotherapy (4).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of reporting quality in clinical practice guidelines for acute myeloid leukemia using the RIGHT checklist

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Acute myeloid leukemia (AML) is an aggressive hematologic malignancy. Clinical practice guidelines (CPGs) on the management of AML have great value in clinical practice. However, the reporting quality of CPGs for AML has not yet been evaluated. This is the first study aiming to evaluate the reporting quality of the most recent AML CPGs published worldwide using the Reporting Items for Practice Guidelines in Healthcare (RIGHT) checklist.Methods: We systematically searched PubMed, Chinese National Knowledge Infrastructure (CNKI), Wanfang, and Chinese Biomedical Literature (CBM) to extract CPGs for AML published between January 2016 and December 2020. Websites for guideline development organizations and medical associations were also searched. Two independent researchers assessed compliance of the guidelines to each of the 35 checklist items and summarized reporting rates for the 7 domains of the RIGHT checklist.Results: We identified 16 guidelines, of which 3 (18.8%) were written in Chinese and 13 (81.3%) were written in English. The average overall reporting rate of the 16 guidelines was 52.9%, and only 7 CPGs (43.8%) had a reporting rate >50%. The average reporting rates of the 7 domains (basic information; background; evidence; recommendations; review and quality assurance; funding, declaration, and management of interests; and other information) were 79.2%, 62.5%, 38.8%, 53.6%, 21.9%, 32.8%, and 43.8%, respectively. For the 35 checklist items, the average reporting rate was 52.9%, and only 16 items had a reporting rate >50%, of which 5 items were reported by all the guidelines. There was 1 item which was not reported by any of the guidelines. Conclusions:The reporting quality of recently published AML guidelines remains poor. While the recommendations of CPGs have great value in clinical practice, the reporting quality of CPGs for AML still needs to be improved.

show abstract

The role of the novel LincRNA uc002jit.1 in NF-kB-mediated DNA damage repair in acute myeloid leukemia cells

Cited by 4 publications

References 35 publications

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors

The Role of PARP1 in Monocyte and Macrophage Commitment and Specification: Future Perspectives and Limitations for the Treatment of Monocyte and Macrophage Relevant Diseases with PARP Inhibitors

A novel prognostic classification integrating lipid metabolism and immune co-related genes in acute myeloid leukemia

Evaluation of reporting quality in clinical practice guidelines for acute myeloid leukemia using the RIGHT checklist

Contact Info

Product

Resources

About